than 40 years underwent uricemia testing (HumaSens). Gout was defined by a validated algorithm (1). Hyperuricemia was defined by capillary level equivalent to plasma uric acid level (PUA) >6 mg/dl (2) and/or urate lowering drug (ULD) prescription. Results: 1.144 participants (mean age 37.7 years; 50.4% men) were included. Prevalence of gout in the entire redressed sample was 3.3% (95% CI 2.2-4.9). The prevalence was 4.1% (1.8-8.9), 2.6% (1.4-4.7), 6.7% (2.5-16.8), and 1.9% (0.5-6.6) for Europeans, Melanesians, Polynesians and other ethnicities, respectively. After adjustment for age and sex, Polynesians showed higher risk for gout than Europeans (adjusted odds ratio ). Prevalence of hyperuricemia, determined in 658 participants, was 67.0% (95% CI 61.9-71.6). Prevalence of hyperuricemia was greater for Polynesians Background: Gout progresses through three stages: hyperuricemia, deposition of monosodium urate (MSU) crystals, and innate immune system response to MSU crystals. Genome wide association studies (GWAS) have provided insight into the molecular control of progression to hyperuricemia. However, less is known about the progression from hyperuricemia to gout. Objectives: To conduct a GWAS for gout (where an immune response to MSU crystals has occurred) using 5,835 cases -the largest GWAS of gout to date. Methods: The GWAS comprised 3 data sets: NZ/Eurogout (2,365 clinicallyascertained cases; 1,485 controls), the Health Professionals Follow-Up (HPFS) and Nurses' Health Studies (NHS) (1,038 cases, self-ascertained using ACR criteria; 1,095 controls), and UK Biobank (2,432 cases, ascertained by self-report of gout, hospital records, and/or use of urate-lowering therapy; 102,989 controls). The NZ/Eurogout samples were genotyped using the Illumina CoreExome v24 bead chip array (547,644 markers), the HPFS/NHS samples using the Illumina OmniExpress v12 bead chip array (730,525 markers), and the UK Biobank samples using an Affymetrix Axiom array (820,967 markers). UK Biobank genotypes had been imputed to ∼73.3M SNPs. Neither the NZ/Eurogout nor NHS/HPFS genotype sets were imputed. Markers common to all three data sets (279,939) were associated with gout (adjusted for sex, age) within each data set separately using PLINK 1.9. An inverse-variance weighted meta-analysis was done with meta v4.4 in R. Results: There were seven loci with genome-wide significant (P<5x10 . However, the differences in pathogenetic, microscopic and clinical aspects between the two diseases are not clear and how CPPD and OA could affect each other is still a matter of debate. Objectives: To assess the differences between CPPD and OA in terms of anatomic alterations of the joint, evaluated with US, and characteristics of the synovial fluid (SF) of knees affected by CPPD and/or OA. Methods: consecutive patients reaching the outpatient clinic for the presence of knee pain and with any amount of joint effusion were eligible for the study. Patients with diagnosis or suspicion of chronic inflammatory rheumatic conditions were excluded. All enrolled patients underwent US of the knee for the assessment of joint effusion (JE), synovial hypertrophy (SH), synovial power Doppler (PD), femuro-tibial osteophytes (FTO) and alterations of the femoral hyaline cartilage (FHC), using a semiquantitative score (0: normal to 3: severe alteration) and finally a US guided aspiration of the SF. SF was examined by optical and polarized light microscopy to determine total and differential white blood cell (WBC) counts, and for crystal identification. The concentration of the main inorganic ions involved in CPP crystal formation (P 2 O
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